Ductal Carcinoma In Situ in Pregnant Women
Akiko Chiba, Emily E. BunceReview Articles, no. 500, 2021
Article DOI: 10.21614/chirurgia.116.5.suppl.S113
Breast cancer is the second most common malignancy affecting pregnant women. Ductal carcinoma in situ (DCIS) during pregnancy has not been well described with limited literature addressing the optimal treatment options. This is important topic as the incidence of pregnancy-associated breast cancer (PABC) has been increasing.
In the United States, 1 in 3000 pregnancies are complicated by breast cancer diagnosis. Most DCIS are screen detected as most patients are asymptomatic. Since routine screening mammogram is not recommended during pregnancy, diagnosis of DCIS without invasive disease is uncommon diagnosis.
Although PABC is reported to account for 0.2-3.8% of all newly diagnosed breast cancer, it has not been defined between the diagnosis of DCIS or invasive breast cancer making true incidence of DCIS in pregnancy difficult to report.
This review summarizes multidisciplinary recommendations for optimal treatment for DCIS diagnosed during pregnancy.
In the United States, 1 in 3000 pregnancies are complicated by breast cancer diagnosis. Most DCIS are screen detected as most patients are asymptomatic. Since routine screening mammogram is not recommended during pregnancy, diagnosis of DCIS without invasive disease is uncommon diagnosis.
Although PABC is reported to account for 0.2-3.8% of all newly diagnosed breast cancer, it has not been defined between the diagnosis of DCIS or invasive breast cancer making true incidence of DCIS in pregnancy difficult to report.
This review summarizes multidisciplinary recommendations for optimal treatment for DCIS diagnosed during pregnancy.
Keywords: ductal carcinoma in situ, pregnancy, diagnosis, treatment
